This proposed study is a double-blind, randomized, placebo-controlled, parallel-group, laboratory study to determine the effects of DMT, plus psychotherapy, on Alcohol Use Disorder.

Start Date01 Apr 2025

Sponsor / Collaborator

Yale University

[+1]

NCT06671977

/ Not yet recruitingPhase 1IIT

Phase 1 Study of the Safety, Tolerability, Electrophysiological Effects and Efficacy of DMT in Humans

The goal of this phase 1 study is to investigate the safety and efficacy of dimethyltryptamine (DMT) in individuals with depression and healthy controls. We hypothesize that administration of DMT will result in decreases in depression, associated symptoms, and neuroplastic changes in depressed subjects. We expect that DMT will induce changes in neuroplasticity as indexed using electroencephalographic (EEG) measures and tasks in both depressed individuals and healthy volunteers, though to different degrees. These neuronal changes may in parallel cause changes in mood measured both in healthy and depressed subjects, which will be captured using appropriate psychometric measures of mood.

Start Date01 Mar 2025

Sponsor / Collaborator

Yale University

NCT06772753

/ RecruitingPhase 1IIT

Investigation of Psychedelic Effects in Psychoactive Substances

The aim of this double-blind, placebo-controlled, within-subjects study is to determine whether other psychoactive substances can produce experiences akin to those seen with classic psychedelics. Screening involves a medical and psychiatric examination, including blood draw, history and physical, interviews, and questionnaires. Eligible participants will then be asked to complete up to 6 experimental drug administration session during which the participants will potentially receive and report on the subjective effects of 6 different psychoactive substances or inactive placebo. Drug assignment for some sessions will be randomized (like flipping a count or rolling a pair of dice), and both participants and study staff will be blind to the drug condition on any given day. Participants will also complete 2 preparation sessions (4 hours total) before the first experimental session, and follow-up visits after each session to discuss and debrief on the participants subjective experience.

Start Date05 Feb 2025

Sponsor / Collaborator

The Johns Hopkins University

100 Clinical Results associated with Dimethyltryptamine

100 Translational Medicine associated with Dimethyltryptamine

100 Patents (Medical) associated with Dimethyltryptamine

3,058

Literatures (Medical) associated with Dimethyltryptamine

01 Dec 2025·FUNCTIONAL & INTEGRATIVE GENOMICS

Unraveling the organellar genomic landscape of the therapeutic and entheogenic plant Mimosa tenuiflora: insights into genetic, structural, and evolutionary dynamics

Article

Author: Prosdocimi, Francisco ; Araújo, Draulio B ; Carnaval, Tatiane K B A ; Costa-Macedo, José V ; Almeida, João V A ; Varani, Alessandro M ; Miranda, Vitor F O ; Trinca, Vitor ; Silva, Saura R

Mimosa tenuiflora, popularly known as "Jurema-Preta", is a perennial tree or shrub native to the tropical regions of the Americas, particularly among Afro-Brazilian and Indigenous Brazilian communities. Known for producing N,N-Dimethyltryptamine, a psychedelic compound with profound psychological effects, Jurema-Preta has been studied for its therapeutic potential in mental health. This study offers a comprehensive analysis of the plastid (ptDNA) and mitochondrion (mtDNA) genomes of M. tenuiflora. The 165,639 bp ptDNA sequence features the classical quadripartite structure with 130 protein-coding genes. Comparative genomics among Mimosa species shows high sequence identity in protein-coding genes, with variation in the rpoC1, clpP, ndhA, and ycf1 genes. The ptDNA junctions display distinct features, such as the deletion of the rpl22 gene, and specific simple sequence repeats highlight genetic variation and unique motifs as valuable genetic markers for population studies. Phylogenetic analysis places M. tenuiflora in the Caesalpinioideae, closely related to M. pigra and M. pudica. The 617,839 bp mtDNA sequence exhibits a complex structure with multiple genomic arrangements due to large repeats, encoding 107 protein-coding genes, including the ptDNA petG and psaA genes, and non-retroviral RNA mitoviruses sequences. Comparative analysis across Fabaceae species reveals limited conservation, emphasizing the dynamic nature of plant mitochondrial genomes. The genomic characterization of M. tenuiflora enhances understanding of its evolutionary dynamics, providing insights for population studies and potential applications in ethnopharmacology and conservation.

01 May 2025·NEUROPHARMACOLOGY

Exploring DMT: Endogenous role and therapeutic potential

Review

Author: Jankowiak-Siuda, Kamila ; Schimmelpfennig, Jakub

N,N-Dimethyltryptamine (DMT) is a naturally occurring amine and psychedelic compound, found in plants, animals, and humans. While initial studies reported only trace amounts of DMT in mammalian brains, recent findings have identified alternative methylation pathways and DMT levels comparable to classical neurotransmitters in rodent brains, calling for a re-evaluation of its biological role and exploration of this inconsistency. This study evaluated DMT's biosynthetic pathways, focusing on indolethylamine N-methyltransferase (INMT) and its isoforms, and possible regulatory mechanisms, including alternative routes of synthesis and how physiological conditions, such as stress and hypoxia influence DMT levels. This review considers the impact of endogenous regulatory factors on DMT synthesis and degradation, particularly under conditions affecting monoamine oxidase (MAO) efficiency and activity. We also examined DMT's potential roles in various physiological processes, including neuroplasticity and neurogenesis, mitochondrial homeostasis, immunomodulation, and protection against hypoxia and oxidative stress. DMT's lipophilic properties allow it to cross cell membranes and activate intracellular 5-HT2A receptors, contributing to its role in neuroplasticity. This suggests DMT may act as an endogenous ligand for intracellular receptors, highlighting its broader biological significance beyond traditional receptor pathways. The widespread evolutionary presence of DMT's biosynthetic pathways across diverse species suggests it may play essential roles in various developmental stages and cellular adaptation to environmental challenges, highlighting the neurobiological significance of DMT and its potential clinical applications. We propose further research to explore the role of endogenous DMT, particularly as a potential neurotransmitter.

01 Apr 2025·FOOD CHEMISTRY

Advanced detection of the protozoacide dimetridazole in complex fluids using cassiterite nanoparticles incorporated carbon black composite

Article

Author: Kiruthiga, G ; Nataraj, Nandini ; Chen, Shen-Ming ; Elshikh, Mohamed S ; Ali, M Ajmal ; Al-Mohaimeed, Amal M ; Chen, Tse-Wei ; Ragumoorthy, Chandini ; Lou, Bih-Show

Dimetridazole (DMT), a nitroimidazole used in veterinary medicine for treating protozoan infections, poses significant carcinogenic and mutagenic risks, necessitating precise monitoring to ensure food safety. We report the development of an advanced electrochemical sensor based on a glassy carbon electrode (GCE) modified with a nanostructured cassiterite (SnO₂)/carbon black (CB) composite, synthesized via hydrothermal and sonochemical techniques. The sensor benefits from SnO₂'s high electrical conductivity, chemical stability, and large bandgap, while CB enhances its performance with superior conductivity. Characterization through various techniques confirmed the composite's nanostructured morphology with an average particle size of 18 nm. Electrochemical analyses revealed a limit of detection (LOD) of 0.004 μM, a limit of quantification (LOQ) of 0.011 μM, and a wide linear range from 0.29 to 204.6 μM. The sensor demonstrated excellent repeatability and reproducibility, with a relative standard deviation (RSD) of 1.6 % and 2.3 %. It also exhibited notable storage stability, retaining 95.8 % of its initial response after 12 days. Real sample analyses showed impressive recovery rates of 97.5 % to 106.4 % for DMT in complex fluids such as food products, biological fluids, synthetic fluids, and environmental samples.

241

News (Medical) associated with Dimethyltryptamine

06 Mar 2025

·www.algernonpharmaceuticals.com

Algernon NeuroScience Engages Netcapital Securities for Planned Regulation A Financing

VANCOUVER, British Columbia, March 06, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that its wholly owned subsidiary Algernon NeuroScience (AGN Neuro), has appointed Netcapital Securities Inc. (“Netcapital Securities”), a FINRA-registered broker-dealer, for its planned Regulation A (Reg A) offering. Netcapital plans to provide broker-dealer and administrative services, excluding underwriting and placement agent services, in connection with this offering. AGN Neuro has filed a Form 1-A with the U.S. Securities and Exchange Commission (SEC), though the offering has not yet been qualified or declared effective by the SEC. AGN Neuro intends to use proceeds from the offering to advance its R&D initiatives, including conducting a randomized, double-blind, placebo-controlled Phase 2a DMT study of 40 actual stroke patients in the third quarter of 2025 in Hungary. The Principal Investigator of the study will be Dr. Sándor Nardai of the National Institute of Mental Health, Neurology and Neurosurgery in Budapest, one of Europe’s leading stroke experts. “We are pleased that Algernon NeuroScience has selected Netcapital Securities as its broker-dealer to provide critical compliance and operational support for this offering,” said Martin Kay, CEO at Netcapital Inc. “We look forward to working with the team at Netcapital Securities as we advance through the SEC qualification process for our planned Reg A offering,” said Christopher J. Moreau, CEO of Algernon NeuroScience. The securities referenced in the planned Reg A offering may not be sold, nor may offers to buy be accepted, before the offering statement filed with the SEC is qualified. This press release is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities. Any offers, solicitations, or sales of securities will be made only by means of an offering circular that meets the requirements of Regulation A. No money or other consideration is being solicited at this time, and if sent in response, it will not be accepted. There is no assurance that the SEC will qualify the offering or that Algernon NeuroScience will successfully raise capital. Investing in early-stage companies involves significant risks, and prospective investors should carefully review all offering materials and risk disclosures before making an investment decision. The Company also announces a grant of 1,405,000 restricted share units pursuant to its RSU Plan (each, an "RSU") to certain executives and directors, of the Company. Each RSU entitles the recipient to receive one common share of the Company or a cash payment equal to the equivalent of one common share of the Company on vesting. The RSUs vest on the date of grant. The Company has also granted 1,000,000 stock options exercisable at $0.09 for five years from the date of grant to certain executives and directors of the Company. The stock options vest on the date of grant. The Company’s 10% rolling stock option plan dated for reference September 11, 2015, as amended on May 21, 2024, and the Company’s 10% rolling restricted share unit plan dated for reference July 23, 2020, as amended on May 21, 2024, were ratified and approved by the shareholders of the Company at its last annual general meeting held on July 10, 2024. Under CSE policy, Shareholders approved the continuation of both Plans until July 10, 2027. The Plans were attached as Schedules B and C respectively to the Information Circular for the July 10, 2024 meeting, and can be accessed under the Company’s SEDAR+ corporate profile at www.sedarplus.ca. The RSUs and stock options are subject to approval by regulatory authorities. About Netcapital Inc. Netcapital Inc. is a fintech company with a scalable technology platform that allows private companies to raise capital online and provides private equity investment opportunities to investors. The Company's consulting group, Netcapital Advisors, provides marketing and strategic advice and takes equity positions in select companies. The Company’s funding portal, Netcapital Funding Portal, Inc., is registered with the SEC and is a member of the Financial Industry Regulatory Authority (“FINRA”), a registered national securities association. The Company’s broker-dealer, Netcapital Securities Inc., is also registered with the SEC and is a member of FINRA. About Algernon NeuroScience Inc. Algernon NeuroScience is a wholly-owned private subsidiary of Algernon Pharmaceuticals and has been established to advance its DMT program for stroke and traumatic brain injury (TBI). For more information, visit https://algernonneuroscience.com. About Algernon Pharmaceuticals Inc. Algernon Pharmaceuticals is a Canadian clinical stage pharmaceutical development company investigating multiple drugs for unmet global medical needs. Algernon Pharmaceuticals is also the parent company of a private subsidiary called Algernon NeuroScience, that is advancing a program investigating a proprietary form of sub-psychedelic DMT for stroke and traumatic brain injury. For more information visit www.algernonpharmaceuticals.com. CONTACT INFORMATION Christopher J. Moreau CEO Algernon Pharmaceuticals Inc. 604.398.4175 Ext 701 info@algernonpharmaceuticals.com investors@algernonpharmaceuticals.com www.algernonpharmaceuticals.com. The CSE does not accept responsibility for the adequacy or accuracy of this release. Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. The Canadian Securities Exchange has not in any way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release. CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to the closing of a private placement, product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law. Released March 6, 2025

Phase 2

03 Mar 2025

·www.drugs.com

Death Risk Doubled For ER Patients On Psychedelics

MONDAY, March 3, 2025 -- People who land in the ER after using hallucinogens are more than twice as likely to die in a handful of years, a new study says. Psychedelics users treated at a hospital are 2.6 times more likely than average folks to die from any cause within five years, researchers reported in the Canadian Medical Association Journal . They specifically were more likely to die by suicide, cancer, lung disease and overdose compared to the general public, researchers found. “The findings highlight the need for ongoing investigation of and communication about both potential benefits and risks from hallucinogen use, particularly use outside clinical trial settings, given rapid increases in general population use,” senior researcher Dr. Marco Solmi , an associate professor of psychiatry at the University of Ottawa, said in a news release. The use of hallucinogens like ketamine , psilocybin, LSD, ayahuasca and ecstasy has rapidly increased since the mid-2010s, driven by clinical trials supporting their potential use in treating mental health and substance use disorders, researchers said in background notes. The percentage of U.S. residents reporting that they used hallucinogens more than doubled from nearly 4% in 2016 to almost 9% in 2021, researchers said. However, there isn’t much data on whether these drugs could increase a person’s risk of death when they’re used outside carefully controlled settings, researchers said. For the new study, researchers analyzed records on ER visits or hospitalizations among more than 11.4 million people 15 and older living in Ontario, Canada from 2006 to 2022. Overall, researchers found a 2.6-fold increased risk of early death among people who required treatment after using a hallucinogen. The risk was even higher -- 3.2-fold -- after researchers excluded people who had mental health or substance use disorders, results show. People who required care for hallucinogen use also had increased risks related to specific causes of death: These risks were higher than those of people who sought hospital care linked to alcohol consumption, but lower than people who needed care for opioid or stimulant use, researchers noted. Psychedelics might increase a person’s risk of suicide if they’re used outside a clinical setting researchers said. People taking hallucinogens also might be liable to take other drugs, increasing their risk of overdose. Further, people who needed hospital care for hallucinogen use were more likely to live in low-income neighborhoods, to have been homeless, to have chronic health problems, and to have been treated for a mental health or substance use disorder in the previous three years, researchers added. “Despite the growing popularity of hallucinogen use, we know surprisingly little about potential adverse effects of hallucinogens, such as mortality risks,” lead researcher Dr. Daniel Myran , research chair in social accountability at the University of Ottawa, said in a news release. “Contemporary clinical trials have not observed any short-term increase in risk of severe adverse events, including death, for trial participants,” Myran said. “However, these studies involve careful supervision and therapy for trial participants and exclude people at high risk of adverse outcomes.” Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

20 Feb 2025

·www.prnewswire.com

Psilera Inc. & atai Life Sciences Announce Licensing Agreement for DMT Patent Portfolio

atai acquires all rights to Psilera's DMT patents and patent applications expanding its intellectual property portfolio Both companies are working to advance next-generation neuroplastogen medicines to treat CNS disorders TAMPA, Fla. and NEW YORK and BERLIN, Feb. 20, 2025 /PRNewswire/ -- Psilera, Inc. ("Psilera"), a biotechnology company developing groundbreaking therapies for hard-to-treat neurological disorders and atai Life Sciences ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced a licensing agreement (the "Agreement") under which atai has acquired Psilera's DMT (N,N-dimethyltryptamine) patent portfolio, including all granted and pending patents related to DMT and other related psychedelics. "We're pleased to collaborate with atai on the DMT patent portfolio given their leadership in psychedelic drug development," said Dr. Chris Witowski, Co-Founder and CEO of Psilera. "This outcome helps us to advance the clinical development of our lead asset PSIL-006 in frontotemporal dementia and our leading next-generation neuroplastogen pipeline." Dr. Srinivas Rao, Co-Founder and CEO of atai, added, "This agreement strengthens our DMT patent portfolio and enables us to further explore the therapeutic potential of DMT for a range of disorders. It also allows us to potentially expand into several other formulations." Since its founding in 2019, Psilera has developed and patented several DMT-specific formulations with optimized bioavailability for clinical and outpatient use across a broad range of neurological indications. Under the terms of the Agreement, Psilera will receive an upfront payment, and, assuming certain conditions are met, will be eligible for payments related to future development milestones, as well as royalties on commercial product sales. Psilera will continue to expand its pipeline of novel neuroplastogens compounds while advancing PSIL-006 to the clinic for first-in-human trials expected in 2026. About Psilera Inc. Psilera is a biopharmaceutical company developing groundbreaking therapeutics for hard-to-treat neurodegenerative diseases. By utilizing their proprietary neuroplastogen drug design platform, Psilera has amassed a leading pipeline of next-generation assets including PSIL-006, a first-in-class therapeutic for the treatment of frontotemporal dementia (FTD). With a deep commitment to scientific excellence and patient centricity, Psilera is transforming the lives of individuals affected by devastating neurodegenerative diseases. Welcome to the new era of mindful medicine. For more information visit . About atai Life Sciences atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. The Company was founded in response to the significant unmet need and lack of innovation in the mental health treatment landscape. atai is dedicated to developing novel, evidence-based therapeutics to treat depression, anxiety and other mental health disorders. atai's vision is to heal mental health disorders so that everyone, everywhere can live a more fulfilled life. For more information, please visit . Forward-looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "anticipate," "initiate," "could," "would," "project," "plan," "potentially," "preliminary," "likely," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements include express or implied statements relating to, among other things: statements regarding our intellectual property, including benefits of the aforementioned licensing agreement for our DMT programs; our business strategy and plans; the potential, success, cost and timing of development of our product candidates, including the progress of preclinical and clinical trials and related milestones; and the plans and objectives of management for future operations, research and development and capital expenditures. Forward-looking statements are neither promises nor guarantees, but involve known and unknown risks and uncertainties that could cause actual results to differ materially from those projected, including, without limitation, the important factors described in the section titled "Risk Factors" in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC"), as such factors may be updated from time to time in atai's other filings with the SEC. atai disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by applicable law. Contact Information Psilera Michael Lauer [email protected] atai Investor Relations [email protected] atai Media Relations [email protected] SOURCE Psilera, Inc WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

License out/in

100 Deals associated with Dimethyltryptamine

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB01488

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Depressive Disorder, Treatment-Resistant	Phase 2	BR	Hanalytics Pte Ltd.	09 Mar 2022
Depressive Disorder, Major	Phase 2	GB	Cybin UK Ltd.	04 Feb 2021
Stroke	Phase 1	NL	Algernon Pharmaceuticals, Inc.	13 Jan 2023
Depressive Disorder	Phase 1	-	ATAI Life Sciences AG	05 Oct 2022
Smoking Cessation	Phase 1	NL	Entheon Biomedical Corp.	22 Feb 2022
Cognition	Phase 1	CH	University of Basel	01 Dec 2020
Brain Injuries, Traumatic	Phase 1	-	Algernon Pharmaceuticals, Inc.	-
Alcoholism	Preclinical	IL	Entheon Biomedical Corp.	01 Mar 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ACTRIMS2024	Not Applicable	Multiple Sclerosis	15	High or very high efficacy DMT	ubszsfjwkg(shakhzdpax) = pffhybgnxi pdpguzuwaq (qsvsvxrcap ) View more	Positive	29 Feb 2024
NCT04673383 (Not provided, Pubmed \| Front Psychiatry)	Phase 1	-	-	SPL026 (DMT fumarate)	dbxrfrgmxo(hknopudesl) = SPL026 was well tolerated, with an acceptable safety profile, with no serious adverse events cvndpgvwcj (rvqptdphqa )	-	11 Jan 2024
NCT05553691 (Corporate Publications) Manual	Phase 1	Depressive Disorder, Major	17	SPL026 (SSRI Cohort)	stighwzcqv(uyyzyzlouz) = sqibqjpeus lqtguiqyic (vrpwopljvn ) View more	Positive	26 Sep 2023
NCT05553691 (Corporate Publications) Manual	Phase 1	Depressive Disorder, Major	17	SPL026 (Non-SSRI Cohort)	stighwzcqv(uyyzyzlouz) = gpjptjglcy lqtguiqyic (vrpwopljvn ) View more	Positive	26 Sep 2023
NCT05573568 (Biospace) Manual	Phase 2	Depressive Disorder, Treatment-Resistant	30	BMND01	lvpzzvfvpf(jdezybmsnu) = No volunteer presented serious adverse events to the 11 different doses tested. hcctuwzktv (llzcedzwqq )	Positive	04 Nov 2022
ECTRIMS2019	Not Applicable	Multiple Sclerosis	256	Patients treated with immunotherapy until gestation	cmqcyxgbpi(qalfzydoma) = lqpjxxpcvr ljraedoysi (puqzvbcqal )	-	10 Sep 2019
ECTRIMS2019	Not Applicable	Multiple Sclerosis	256	Patients who never had a therapy	cmqcyxgbpi(qalfzydoma) = pqozmozbfm ljraedoysi (puqzvbcqal )	-	10 Sep 2019
ECTRIMS2018	Not Applicable	Brain atrophy	520	DMT	hejjqzmcfi(ypsqqcotju) = zwmvngzhws tgfxxujgfj (owlnxmggnr ) View more	-	09 Oct 2018

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis